If approved, bemotrizinol could significantly improve sun protection for Americans by offering better defense against UVA rays, which are linked to skin aging and cancer. Its photostability ensures longer-lasting protection, and its inclusion in sunscreen formulations could lead to lighter, more comfortable products that encourage regular use. This is particularly important as skin cancer rates remain high in the U.S., with melanoma claiming approximately 20 lives daily. However, the FDA's stringent regulatory process has delayed the introduction of such advanced ingredients, potentially leaving Americans with less effective sun protection compared to other countries. Dermatologists stress that while bemotrizinol is a promising addition, it will not replace the need for comprehensive sun safety practices, including wearing SPF 30 or higher, seeking shade, and using protective clothing.